14 results · 23ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

UASure II Blood Uric Acid Monitoring System

FDA 510(k)
FDA Class 1 ·Clinical Chemistry

Artman Instruments

FDA UDI
Wise Linkers, LLC·D1272422091·Tweed Omega Orthodontic Loop Forming Pliers ARTMAN

LC-DCP

FDA UDI
Synthes GmbH·10886982168290·2.7MM LC-DCP® PLATE 9 HOLES/86MM

Portex

FDA UDI
ICU MEDICAL, INC.·15019517077612·

Pulse oximeter NBM-200

FDA 510(k)
FDA Class 2 ·Cardiovascular

CONTROL PLASMA N AND CONTROL PLASMA P

FDA 510(k)
FDA Class 2 ·Hematology

DEXCOM G7 CONTINUOUS GLUCOSE MONITORING SYSTEM

FDA Adverse Event
Malfunction ·DEXCOM, INC.·Product code QBJ·September 2, 2025

GMK SPHERE TOTAL KNEE SYSTEM

FDA Adverse Event
Injury ·MEDACTA INTERNATIONAL SA·Product code JWH·February 26, 2025

JOSTENT GRAFTMASTER

FDA Adverse Event
Injury ·ABBOTT VASCULAR-CARDIAC THERAPIES·Product code MAF·November 19, 2008

COLLEAGUE

FDA Adverse Event
Malfunction ·BAXTER HEALTHCARE - SINGAPORE·Product code FRN·September 9, 2011

GYNECARE TVT OBURATOR SYSTEM

FDA Adverse Event
Injury ·ETHICON INC.·Product code OTN·July 23, 2013

TRUE METRIX

FDA Adverse Event
Malfunction ·TRIVIDIA HEALTH INC·Product code NBW·December 3, 2019

OXF CMNTLS IMPLANT INSERT

FDA Adverse Event
Malfunction ·BIOMET UK LTD.·Product code LXH·November 25, 2019

St. Jude Medical Confirm Rx Insertable Cardiac Monitor, REF DM3500, Sterile. Product Usage: The St. Jude Medical Confirm Rx insertable cardiac monitor (ICM) is designed to detect arrhythmias and wirelessly transmit data to the Merlin.net Patient Care Network (PCN). It is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.

FDA Enforcement
Class II ·Terminated·Abbott·May 1, 2019